Cramer: This CEO should be next Bond villain

"I don't know if Daniel Craig is going to stay as [James] Bond," said Jim Cramer said on Thursday's "Squawk on the Street." "But THIS is the villain." (Tweet This)

Cramer was speaking about none other than Turing Pharmaceuticals CEO Martin Shkreli.

Shkreli was arrested by the FBI at his residence Thursday morning on securities fraud charges relating to his former company, Retrophin.

Cramer said Shkreli tweeted in the past that he was not selling RTRX while he was engaged in the sale of stock.

"You know when you're saying you're a buyer when you're actually a seller, that may be alleged, you don't know, you can't be for sure, innocent until proven guilty, securities fraud," said Cramer.

The controversial pharmaceutical executive also made headlines in September when he raised the price of the toxoplasmosis-fighting drug, Daraprim, by more than 5,000 percent.

In addition to heading Turing, Shkreli also invested in a small biotech company known as Kalobios Pharma. Kalobios stock has been incredibly volatile after the report of his arrest, briefly dipping below 53 percent Thursday morning.

A press conference regarding Shkreli's indictment was held Thursday in which U.S. Attorney Robert Capers said Shkreli "essentially ran his companies like a Ponzi scheme."

Turing Pharmaceuticals did not immediately respond to CNBC's request for comment.

Disclosure: Shkreli previously interned at Cramer's former firm, Cramer-Berkowitz, as part of a New York City internship program. Cramer said his former partner hired Shkreli after he left the firm.

— Reuters contributed to this report.